Assessing the value of omalizumab for pediatric asthma in China : a multicriteria decision analysis

Tools

Yu, Yuncui and Cao, Wang and Xiao, Yue and Wei, Jing and Huang, Huijie and Li, Ang and Zhao, Mingyang and Hu, Lihua and Poonsiri, Chittawan and Teerawattananon, Yot and Morton, Alec and Guo, Peng (2025) Assessing the value of omalizumab for pediatric asthma in China : a multicriteria decision analysis. Healthcare, 13 (19). 2385. ISSN 2227-9032 (https://doi.org/10.3390/healthcare13192385)

[thumbnail of Yu-etal-Healthcare-2025-Assessing-the-value-of-omalizumab-for-pediatric-asthma]
Preview
 Text. Filename: Yu-etal-Healthcare-2025-Assessing-the-value-of-omalizumab-for-pediatric-asthma.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo
Download (608kB)| Preview

Abstract

Background/Objectives: This study aimed to apply a multicriteria decision analysis to assess the comprehensive value of omalizumab for moderate to severe pediatric asthma in China. Methods: A multidisciplinary panel of 17 experts assessed the value of omalizumab plus the standard of care (SOC) using SOC alone as a comparator. We developed a hierarchical criteria system with six main domains and 15 specific criteria. To establish a comprehensive evidence matrix, we integrated findings from a systematic literature review (SLR) and a real-world pharmacovigilance study based on the FAERS database. The overall estimated value of each strategy was obtained by combining the criterion weights with the score of each strategy in each criterion. A sensitivity analysis was conducted to validate the robustness of the results. Results: According to the AHP methods, the following weights were assigned to the criteria: safety (38.55%), effectiveness (28.85%), economics (9.65%), innovation (8.24%), accessibility (7.84%), and applicability (6.88%). Based on the evidence matrix, omalizumab plus SOC scored higher than the SOC in effectiveness (2.53 vs. 1.94) and innovation (0.70 vs. 0.15). When the weight and score of each strategy in each criterion were combined, the overall estimated values were 7.40 points for omalizumab plus SOC and 7.19 points for SOC. Conclusions: Adding omalizumab was assessed as a conditionally recommended strategy for treating moderate to severe asthma in Chinese children.

ORCID iDs

Yu, Yuncui, Cao, Wang, Xiao, Yue, Wei, Jing, Huang, Huijie, Li, Ang, Zhao, Mingyang, Hu, Lihua, Poonsiri, Chittawan, Teerawattananon, Yot, Morton, Alec ORCID logoORCID: https://orcid.org/0000-0003-3803-8517 and Guo, Peng;
CORE (COnnecting REpositories)